237
Views
23
CrossRef citations to date
0
Altmetric
Articles

Syndecan-1 in Multiple Myeloma: Relationship to Conventional Prognostic Factors

, &
Pages 221-228 | Published online: 04 Sep 2013

References

  • Forester, J. and Paraskevas, E (2000) In: Lee, G.R., Foerster, J., Lukens, J., Paraskevas, Greer, J.P. and Rodgers, G.M., eds, Multiple Myeloma in Wintrobe's Clinical Hematology (Williams & Wilkins Company Vol. 10, 99, pp 2631–2632.
  • Xu, J.L., Lai, R., Kinoshita, T., Nakashima, N. and Nagasaka, T. (2002) "Proliferation, apoptosis and intratumoral vascular-ity in multiple myeloma: correlation with the clinical stage and cytological grade", J. Clin. Pathol. 55(7), 530–534.
  • Kaneko, M., Kanda, Y., Oshima, K., Nannya, Y., Suguro, M., Yamamoto, R., Chizuka, A., Hamaki, T., Matsuyama, T., Takezako, N., Miwa, A. and Togowa, A. (2002) "Simple prognostic model for patients with multiple myeloma: a single center study in Japan", Ann. Hematol. 81, 33–36.
  • Tribalto, M., Amadori, S., Cudillo, L., Caravita, T., Del Poeta, G., Meloni, G., Avvisati, G., Petrucci, M.T., Pulosoni, A., Leone, G., Sica, S., Martelli, M., Tabilio, A., Fioritoni, G., Majolino, I. and Mandelli, E (2000) "Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter study", Hemato-logica 85, 52–58.
  • Patriarca, F., Damiani, D., Fanin, R., Grimaz, S., Geromin, A., Cerno, M., Sperotto, A., Silvestri, F., Zaja, F. and Baccarani, M. (2000) "High dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome", Hematologica 85(3), 269–274.
  • Palumbo, A., Triolo, S., Baldini, L., Callea, V, Capaldi, A., De Stefano, V, Grasso, M., Liberati, M., Lotesoriere, C., Maceno, R., Marmont, E, Musto, P., Petrucci, M.T., Spriano, M., Pilleri, A. and Boccadoro, M. (2000) "Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients", Hematologica 85(5), 508–513.
  • Martinelli, G., Terragna, C., Zamagni, E., Ronconi, S., Tosi, P., Lemoli, R.M., Bandini, G., Motta, M.R., Testoni, N., Amabile, M., Ottaviani, E., Vianelli, N., de Vivo, A., Gozzetti, A., Tura, S. and Cavo, M. (2000) "Molecular remission after allogenic or autologous transplantation of hemopoieitic stem cell for multiple myeloma", J. Clin. Oncol. 18(11), 2273–2281.
  • Maisnar, V, Touskova, N., Maly, J., Krejsek, J., Kmonicek, M. and Kopecky, O. (2002) "Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma", Vnitr. Leuk. 48(4), 290–297.
  • Fakan, E, Boudova, L. and Hejda, C. (2002) "Syndecan-1 (CD138) an immunohistochemical marker of plasma cell tumors", Cesk. Path. 38(1), 33–36.
  • Bayer-Garner, I.B., Joseph, L., Sanderson, R.D. and Smoller, B.R. (2003) "Expression of syndecan-1 is a senesitive marker for cutaneous plasmacytoma", J. Cutan. Pathol. 30(1), 18–22.
  • Sanderson, R.D. and Borset, M. (2002) "Syndecan-1 in B lymphoid malignancies", Ann. Hematol. 81(3), 125–135.
  • Derksen, P.W., Keehnen, R.M., Evers, L.M., van Oers, M.H., Spaargaren, M. and Pals, S.T. (2002) "Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes met signaling in multiple myeloma", Blood 99(4), 1405–1410.
  • Ridley, R.C., Xiao, H., Hata, H., Woodlift J., Epstein, J. and Sanderson, R.D. (1993) "Expression of syndecan regulates human myeloma plasma cell adhesion to Type I collagen", Blood 81(3), 767–774.
  • Liebersbach, B.F. and Sanderson, R.D. (1994) "Expression of syndecan-1 inhibits cell invasion into type I collagen", J. Biol. Chem. 269(31), 20013–20019.
  • Teoh, G. and Anderson, K.C. (1997) "Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma", Hematol. Oncol. Clin. North Am. 11(1), 27–42.
  • Yang, Y., Yaccoby, S., Liu, W., Langford, J.K., Pumphrey, C.Y., Theus Epestein, J. and Sanderson, R.D. (2002) "Soluble syndecan-1 promotes growth of meloma tumor in vivo", Blood 100(2), 610–617.
  • Seidel, C., Sundan, A., Hjorth, M., Turesson, I., Dahl, I.M., Abildgaard, N., Waage, A. and Borset, M. (2000) "Syndecan-1: a new independent prognostic marker in multiple myeloma", Blood 95, 388–392.
  • Seidel, C., Borset, M., Turesson, I., Abildgaard, N., Sundan, A. and Waage, A. (1998) "Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study group", Blood 91(3), 806–812.
  • Dhodapkar, M.W., Kelly, T., Theus, A., Athota, A.B., Barlogie, B. and Sanderson, R.D. (1997) "Elevated levels of shed syndecan-1 correlate with tumor mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma", Br. J. Haematol. 99, 368–371.
  • Salmon, S.E. and Smith, B.A. (1970) "Immunoglobulin synthesis and total body tumor cell memberane in IgG multiple myeloma", J. Clin. Investig. 88, 1114–1118.
  • Min, R., Li, Z., Epstein, J., Barlogie, B. and Yi, Q. (2002) "32 microglobulinas a negative growth regulator of myeloma cells", Br. J. Haematol. 118(2), 495–505.
  • Dhodapkar, M.V., Abe, E., Theus, A., Lacy, M., Langford, J.K., Barlogie, B. and Sanderson, R.D. (1998) "Syndecan-1 is a multifunctional regulator of myeloma pathobiology; control of tumor survival, growth and bone cell differentiation", Blood 91(8), 2679–2688.
  • Li, X., Zhang, X., Lu, Z., et al. (2001) "Relative study of soluble syndecan-1 and prognosis of patients with multiple myel-oma", Zhonghua Xue Ye Xue Za Zhi 22(6), 303–305, [absract] article in chinesse.
  • Holen, I., Drury, N.L., Hargreaves, PG. and Croucher, P.I. (2001) "Evidence of a role for a non-matrix-type metallopro-teinase activity in shedding of syndecan-1 from human myeloma cells", Br. J. Haematol. 114(2), 414–421.
  • Kelly, T., Borset, M., Abe, E., Gaddy-Kurten, D. and Sanderson, R.D. (2000) "Matrix metalloproteinases in multiple myeloma", Leuk. Lymphoma 37(3-4), 273–281.
  • Kaushal, G.P., Xiong, X., Athota, A.B., Rozypal, T.L., Sanderson, R.D. and Kelly, T. (1999) "Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase -9", Br. J. Haematol. 104(2), 365–373.
  • Bayer-Garner, I.B., Sanderson, RD., Dhodapkar, M.V., Owens, R.B. and Wilson, C.S. (2001) "Syndecan(CD138): immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions", Mod. Pathol. 14(10), 1052–1058.
  • Wijdenes, J., Vooijs, W.C., Clement, C., Post, J., Morard, E, Vita, N., Laurent, P., Sun, R.X., Klein, B. and Dore, J.M. (1996) "A plasmacyte selective monoclonal antibody (B-B4) recognizes syndecan-1", Br. J. Haematol. 94(2), 318–323.
  • Jourdan, M., Ferlin, M., Legouffe, E., Horvathova, M., Liautard, J., Rossi, J.F., Wijdenes, J., Brochier, J. and Klein, B. (1998) "The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells", Br. J. Haematol. 100(4), 637–646.
  • Subramanian, S.V., Fitzgerald, Mi. and Bernfield, M. (1997) "Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation", J. Biol. Chem. 272(23), 14713–14720.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.